|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-5-8
|
|
pubmed:abstractText |
A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0016-5085
|
|
pubmed:author |
pubmed-author:BornsteinJeffreyJ,
pubmed-author:FeaganBrian GBG,
pubmed-author:FedorakRichard NRN,
pubmed-author:HernandezChitoC,
pubmed-author:International Efficacy of Natalizumab in Crohn's Disease Response and...,
pubmed-author:LashnerBret ABA,
pubmed-author:PanaccioneRemoR,
pubmed-author:PresentDaniel HDH,
pubmed-author:RutgeertsPaul JPJ,
pubmed-author:SandbornWilliam JWJ,
pubmed-author:SpehlmannMartina EME,
pubmed-author:TarganStephan RSR,
pubmed-author:TulassayZsoltZ,
pubmed-author:VolfovaMiroslavaM,
pubmed-author:WolfDouglas CDC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
132
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1672-83
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:17484865-Adult,
pubmed-meshheading:17484865-Aged,
pubmed-meshheading:17484865-Aged, 80 and over,
pubmed-meshheading:17484865-Antibodies, Monoclonal,
pubmed-meshheading:17484865-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:17484865-C-Reactive Protein,
pubmed-meshheading:17484865-Crohn Disease,
pubmed-meshheading:17484865-Dose-Response Relationship, Drug,
pubmed-meshheading:17484865-Double-Blind Method,
pubmed-meshheading:17484865-Female,
pubmed-meshheading:17484865-Humans,
pubmed-meshheading:17484865-Immunogenetics,
pubmed-meshheading:17484865-Inflammation,
pubmed-meshheading:17484865-Infusions, Intravenous,
pubmed-meshheading:17484865-Male,
pubmed-meshheading:17484865-Middle Aged,
pubmed-meshheading:17484865-Quality of Life,
pubmed-meshheading:17484865-Remission Induction,
pubmed-meshheading:17484865-Time Factors,
pubmed-meshheading:17484865-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
|
|
pubmed:affiliation |
Inflammatory Bowel Disease Center and Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA. targans@cshs.org
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
